Monensin (Synonyms: Monensin A)

Name: Monensin
Brand: MedChemExpress
SKU: HY-N4302
Rating: 5.0 (38 reviews)

Cat. No.: HY-N4302 Purity: 98.07%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Monensin (Monensin A), an orally active antibiotic, is an ionophore that mediates Na⁺/H⁺ exchange. Monensin is a potent Wnt signaling inhibitor. Monensin causes a marked enlargement of the multivesicular bodies (MVBs) and regulates exosome secretion. Monensin can be used for bacterial, fungal, and parasitic infections research, and shows anticancer effects.

For research use only. We do not sell to patients.

CAS No. : 17090-79-8

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 38 publication(s) in Google Scholar

Other Forms of Monensin:

Monensin sodium In-stock

38 Publications Citing Use of MCE Monensin

Cell Migration/Invasion Assay

Cell Imaging/Staining

RT-PCR

: Monensin purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2024 Dec 30;9(1):367. [Abstract]; Cellular BiP-IRF2BP2 interactions shown by Western blot analysis of co-immunoprecipitation in MG132-pretreated (5 μM, 0.5 h) Raw264.7 cells which were treated with acidized medium (AcM) or with AcM plus Monensin (0.1 μM) in the presence of LPS and MG132 (0.5 μM) for 6 h.

: Monensin purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2024 Dec 30;9(1):367. [Abstract]; Il1b expressions in BMDMs isolated from Hspa5^f/f or Hspa5^f/f; Lyz2-Cre mice treated with or without Monensin (1 μM), under stimulation of LPS for 24 h.

: Monensin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jul 18;16(1):6621. [Abstract]; The impact of different concentrations of monensin on the subcellular localization of YFP-ATG8e. 5-day-old YFP-ATG8e transgenic seedlings were treated with different concentrations of Monensin (5-40 μM; 1 h) in 1/2MS liquid medium, followed by confocal microscopy observation.

: Monensin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jul 18;16(1):6621. [Abstract]; Detection of ROS generation after monensin treatment. 5-day-old mCherry-ATG8f seedlings were subjected to Monensin (20 μM; 1 h) treatment. The ROS-sensitive dye H2DCFDA (1 μM) was incubated 10 min prior to confocal imaging. The images were shown with LUT pseudocolor scale.

: Monensin purchased from MedChemExpress. Usage Cited in: Proc Natl Acad Sci U S A. 2025 Jul 15;122(28):e2501347122. [Abstract]; Boyden chamber transwell assays on mesenchymal NSCLC cells treated with indicated doses of Monensin (100-500 nM; 24 h). Migrated and invaded cells were quantified.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Antibiotic Isoform Specific Products:

View All Isoforms

Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

View All Parasite Isoform Specific Products:

View All Isoforms

Amebae Coccidia Leishmania Mite Plasmodium Toxoplasma Trypanosoma Schistosome

View All Wnt Isoform Specific Products:

View All Isoforms

Wnt1 Wnt3 Wnt5 Wnt7 Wnt11

Biological Activity
Purity & Documentation
References
Customer Review

Description

Cellular Effect

Cell Line	Type	Value	Description	References
BALB/3T3	IC₅₀	20.89 μM Compound: MON	Cytotoxicity against mouse BALB/3T3 cells Cytotoxicity against mouse BALB/3T3 cells	[PMID: 26338363]
Hepatocyte	IC₅₀	< 0.001 nM Compound: Monensin	Antimicrobial activity against Plasmodium falciparum NF54 schizonts in mammalian hepatocytes after 96 hrs Antimicrobial activity against Plasmodium falciparum NF54 schizonts in mammalian hepatocytes after 96 hrs	[PMID: 18212104]
Hepatocyte	IC₅₀	< 0.001 nM Compound: Monensin	Antimicrobial activity against Plasmodium yoelii 265 liver infected in mammalian hepatocytes after 48 hrs Antimicrobial activity against Plasmodium yoelii 265 liver infected in mammalian hepatocytes after 48 hrs	[PMID: 18212104]
LoVo	IC₅₀	1.09 μM Compound: MON	Antiproliferative activity against human LoVo cells Antiproliferative activity against human LoVo cells	[PMID: 26338363]
MV4-11	IC₅₀	0.09 μM Compound: MON	Antiproliferative activity against human MV4-11 cells Antiproliferative activity against human MV4-11 cells	[PMID: 26338363]

In Vitro

Monensin (1-5 μM; 48 h) results in a marked decrease in viability in a dose-dependent manner^[1].
Monensin (1-5 μM; 24 h) shows a statistically significant induction of apoptosis^[1].
Monensin (0.1-1 μM; 24 h) inhibits pEGFR and its downstream targets pAKT and pERK^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	SCC9, SCC25, and GM-38 cell lines
Concentration:	1-5 μM
Incubation Time:	48 h
Result:	Resulted in a marked decrease in viability in a dose-dependent manner.

Apoptosis Analysis^[1]

Cell Line:	SCC25 cells
Concentration:	1 μM, or 5 μM
Incubation Time:	24 hours
Result:	Induced a potent apoptotic response.

Western Blot Analysis^[1]

Cell Line:	SCC9 and SCC25 cells
Concentration:	0.1 μM, or 1 μM
Incubation Time:	24 hours
Result:	Induced approximately a 50% inhibition of EGF-treated SCC9 cells with respect to pEGFR and its downstream targets pAKT and pERK.

In Vivo

Monensin (10 mg/kg; po; daily; for 6 weeks) suppresses progression of the intestinal tumors without any sign of toxicity on normal mucosa in multiple intestinal neoplasia (Min) mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Multiple intestinal neoplasia (Min) mice (four-week-old) ^[2]
Dosage:	10 mg/kg
Administration:	Orally application; daily; for 6 weeks
Result:	Suppressed progression of the intestinal tumors without any sign of toxicity on normal mucosa.

Molecular Weight

670.87

Formula

C₃₆H₆₂O₁₁

CAS No.

17090-79-8

Appearance

Solid

Color

White to light yellow

SMILES

C[C@]1([C@]2([H])O[C@@](CC2)([C@]3([H])O[C@]([C@@]4([H])O[C@](O)([C@@H](C[C@@H]4C)C)CO)([H])C[C@@H]3C)CC)O[C@@]5(CC1)O[C@]([C@@H]([C@H](C5)O)C)([H])[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O

Structure Classification

Others

Initial Source

Microorganisms

Streptomyces spp.

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (149.06 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.4906 mL	7.4530 mL	14.9060 mL
5 mM	0.2981 mL	1.4906 mL	2.9812 mL
10 mM	0.1491 mL	0.7453 mL	1.4906 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (3.73 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 98.07%

Select Batch:

Data Sheet (288 KB) SDS (254 KB)

COA (264 KB) HNMR (434 KB) RP-HPLC (220 KB) MS (68 KB)

Handling Instructions (2659 KB)

References

[1]. Dayekh K, et al. Monensin inhibits epidermal growth factor receptor trafficking and activation: synergistic cytotoxicity in combination with EGFR inhibitors. Mol Cancer Ther. 2014 Nov;13(11):2559-71. [Content Brief]

[2]. Tumova L, et al. Monensin inhibits canonical Wnt signaling in human colorectal cancer cells and suppresses tumor growth in multiple intestinal neoplasia mice. Mol Cancer Ther. 2014 Apr;13(4):812-22. [Content Brief]

[3]. Youhua Huang, et al. Autophagy Participates in Lysosomal Vacuolation-Mediated Cell Death in RGNNV-Infected Cells. Front Microbiol. 2020 Apr 30:11:790. [Content Brief]

[4]. Ariel Savina, et al. Rab11 promotes docking and fusion of multivesicular bodies in a calcium-dependent manner. Traffic. 2005 Feb;6(2):131-43. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.4906 mL	7.4530 mL	14.9060 mL	37.2650 mL
	5 mM	0.2981 mL	1.4906 mL	2.9812 mL	7.4530 mL
	10 mM	0.1491 mL	0.7453 mL	1.4906 mL	3.7265 mL
	15 mM	0.0994 mL	0.4969 mL	0.9937 mL	2.4843 mL
	20 mM	0.0745 mL	0.3727 mL	0.7453 mL	1.8633 mL
	25 mM	0.0596 mL	0.2981 mL	0.5962 mL	1.4906 mL
	30 mM	0.0497 mL	0.2484 mL	0.4969 mL	1.2422 mL
	40 mM	0.0373 mL	0.1863 mL	0.3727 mL	0.9316 mL
	50 mM	0.0298 mL	0.1491 mL	0.2981 mL	0.7453 mL
	60 mM	0.0248 mL	0.1242 mL	0.2484 mL	0.6211 mL
	80 mM	0.0186 mL	0.0932 mL	0.1863 mL	0.4658 mL
	100 mM	0.0149 mL	0.0745 mL	0.1491 mL	0.3727 mL

Monensin Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Monensin (Synonyms: Monensin A)

Customer Review

Other Forms of Monensin:

Monensin Related Antibodies

38 Publications Citing Use of MCE Monensin

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Antibiotic Isoform Specific Products:

View All Parasite Isoform Specific Products:

View All Wnt Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Monensin Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Monensin Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report